The relationship between CSF α-synuclein and established core biomarkers such as Aβ42 and p-tau could advance its diagnostic accuracy and significantly discriminate Alzheimer’s disease with primary α-synucleinopathies. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.